Evidence map›Paper›PMID 42118447›Full record

SynthesisImmunologic research2026

Anti-neutrophil cytoplasmic antibodies in interstitial lung disease: results from a cross-sectional study and meta-analysis.

Dongru Du, Faping Wang, Min Zhu, Yali Zhang, Guangyue Zhang, Qibing Xie, Geng Yin, Jianqun Yu, Xiaoyan Lv, Lili Jiang and 2 more

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dongru Du *Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
Faping Wang *Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
Min Zhu *Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yali Zhang *Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
Guangyue ZhangDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Qibing XieDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Geng YinDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Jianqun YuDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China.
Xiaoyan LvDepartment of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China.
Lili JiangDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Xiaoju TangDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China. huaxitangxiaoju@wchscu.cn.
Fengming LuoDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China. fengmingluo@outlook.com.

Funding

National Natural Science Foundation of China 82400084
6 · The paper itself

Abstract

This study aims to investigate the prevalence, clinical characteristics, and prognostic significance of anti-neutrophil cytoplasmic antibodies (ANCA) across different subtypes of interstitial lung disease (ILD), specifically idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD (CTD-ILD) without ANCA-associated vasculitis (AAV), and AAV-ILD. A cross-sectional study was conducted to evaluate the positivity rate and clinical characteristics of ANCA in ILD. In the following meta-analysis, PubMed, Web of Science and Scopus were searched for eligible studies reporting positivity rate of ANCA in ILD. The pooled positivity rates of ANCA, MPO and PR3 in ILD were calculated, and survival outcome between ANCA-positive and ANCA-negative ILD patients were compared. Sensitivity analyses, subgroup analyses and meta-regression was also conducted. A total of 217 ILD patients were enrolled in this cross-sectional study, with an ANCA positivity rate of 7%. In the meta-analysis, with 24 studies and 4,424 patients, the pooled positivity rate of ANCA in IPF, CTD-ILD without AAV, and AAV-ILD were 9%, 15% and 97%, respectively. In patients with IPF, patients with ANCA positivity were more likely to develop honeycombing (OR 2.70, 95%CI 1.09, 6.70, p = 0.03). No significant difference was observed in survival time between IPF patients with or without ANCA positivity (HR 1.18, 95%CI 0.73, 1.90). The positivity rate of ANCA varies significantly across different subtypes of ILD. Future research should focus on the characteristics and prognostic value of ANCA positivity in other ILD subtypes.

Indexed as

Antibodies, Antineutrophil CytoplasmicLung Diseases, InterstitialAgedAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisCross-Sectional StudiesFemaleHumansMaleMiddle AgedPrognosisAntibodies, Antineutrophil CytoplasmicANCACross-sectional studyInterstitial lung diseaseMeta-analysis

Identifiers

PMID42118447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.